Article Information
History
- November 23, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Prasanna Jagannathan1,2,*,
- Jason R. Andrews1,‡,
- Hector Bonilla1,‡,
- Haley Hedlin3,‡,
- Karen B. Jacobson1,
- Vidhya Balasubramanian3,
- Natasha Purington3,
- Savita Kamble4,
- Christiaan R. de Vries1,
- Orlando Quintero1,
- Kent Feng4,
- Catherine Ley1,
- Dean Winslow1,
- Jennifer Newberry5,
- Karlie Edwards1,
- Colin Hislop6,
- Ingrid Choong6,
- Yvonne Maldonado7,
- Jeffrey Glenn1,2,
- Ami Bhatt1,8,
- Catherine Blish1,
- Taia Wang1,2,
- Chaitan Khosla9,
- Benjamin A. Pinsky1,10,
- Manisha Desai3,
- Julie Parsonnet1 and
- Upinder Singh1,2
- 1Department of Medicine, Stanford University, Stanford, CA, USA
- 2Department of Microbiology and Immunology, Stanford University, Stanford, CA USA
- 3Quantitative Sciences Unit, Stanford University, Stanford, CA, USA
- 4Stanford Center for Clinical Research, Stanford University, Stanford, CA USA
- 5Department of Emergency Medicine, Stanford University, Stanford, CA, USA
- 6Department of Pediatrics, Stanford University, Stanford, CA, USA
- 7Eiger BioPharmaceuticals, Palo Alto, CA, USA
- 8Department of Genetics, Stanford University, Stanford, CA USA
- 9ChEM-H, Stanford University, Stanford, CA USA
- 10Department of Pathology, Stanford University, Stanford, CA USA
- ↵*Correspondence to: Prasanna Jagannathan, Stanford University, 240 Pasteur Drive, Room 3456, Stanford, CA 94305. prasj{at}stanford.edu; and Upinder Singh, Stanford University, 300 Pasteur Drive, Suite 154, Stanford, CA 94305. usingh{at}stanford.edu.
↵‡ These authors contributed equally (listed alphabetically)
Posted November 23, 2020.
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
